Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults.
Tools
Tools
van Damme, Pierre, Kafeja, Froukje, Anemona, Alessandra, Basile, Venere, Hilbert, Anne Katrin, De Coster, Ilse, Rondini, Simona, Micoli, Francesca, Qasim Khan, Rana M, Marchetti, Elisa, Di Cioccio, Vito, Saul, Allan, Martin, Laura B and Podda, Audino (2011) Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PloS one, 6 (9). e25398. ISSN 1932-6203
Abstract
Typhoid fever causes more than 21 million cases of disease and 200,000 deaths yearly worldwide, with more than 90% of the disease burden being reported from Asia. Epidemiological data show high disease incidence in young children and suggest that immunization programs should target children below two years of age: this is not possible with available vaccines. The Novartis Vaccines Institute for Global Health developed a conjugate vaccine (Vi-CRM₁₉₇) for infant vaccination concomitantly with EPI vaccines, either starting at 6 weeks with DTP or at 9 months with measles vaccine. We report the results from a Phase 1 and a Phase 2 dose ranging trial with Vi-CRM₁₉₇ in European adults.
| Item Type: | Article |
|---|---|
| Related URLs: | |
| Related URLs: | |
| Date Deposited: | 13 Oct 2015 13:14 |
| Last Modified: | 13 Oct 2015 13:14 |
| URI: | https://oak.novartis.com/id/eprint/6437 |